The Mechanism of Action of Ribavirin on Bunyavirus Infected Cells
Abstract:
Ribavirin 1-B-D-ribofuranosyl-1-1,2,4-triazole-3-carboxamide or Virazole is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. The drug was approved by the Food and Drug Administration in 1986 for aerosol use in infants with serious infections due to respiratory syncytial virus RS. Ribavirin is and has been under clinical investigation against a variety of viral illness, including those due to influenza virus, Lassa fever, Korean hemorrhagic fever with renal syndrome KHFS and Human immunodeficiency virus HIV. There has been a great deal of clinical interest in utilizing ribavirin for HIV infections. It has been reported to slow the development of AIDS in HIV infected patients McCormick et al., 1984. We describe here the reported mechanisms of action of this newly licensed drug. jg